This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Common semaglutide side effects include nausea, vomiting, ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

According to the Gallup National Health and Well-Being Index, 37% of U.S. adults now report obesity, down from 39.9% three ...

The study will include around 200 participants aged 65 or older with BMI of at least 35 starting semaglutide therapy.

Bariatric surgery uptake has decreased since the fourth quarter of 2022, coinciding with a rise in prescriptions of semaglutide and tirzepatide for adults with obesity, according to a research letter ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday. "Until now, neither of these ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to ...

The drug behind Ozempic has been found to restore joint cartilage in osteoarthritis, through a mechanism that works independently of weight loss.